Preliminary results of a phase Ⅱ prospective clinical study of early-stage nasal NK/T-cell lymphoma with extended involved-field intensity-modulated radiotherapy
Abstract：Objective To investigate the feasibility of the scheme of target volume delineation with extended involved-field intensity-modulated radiotherapy (IMRT) for patients with early-stage nasal NK/T-cell lymphoma (NC-NKTL). Methods Twenty-one patients with stage IE-IIE NC-NKTL were treated with short-course chemotherapy combined with radiotherapy from 2011 to 2013. The majority of patients received the GELOX regimen. All patients received extended involved-field IMRT with a dose of 54.6 Gy in 26 fractions for gross tumor volume, 50.7 Gy in 26 fractions for high-risk clinical target volume (CTV), and 45.5 Gy in 26 fractions for low-risk CTV. The dose distribution, short-term treatment outcomes, and adverse reactions were analyzed. Results The 2-year sample size was 12. The 2-year follow-up rate was 100%. The 2-year local control rate (LRC) was 100%. The 2-year overall and progression-free survival rates were 90.5% and 90.5%, respectively. The median coverage rates of planning target volumes with 90% of the prescribed doses of 54.6 Gy, 50.7 Gy, and 45.5 Gy were 99.8%, 99.6%, and 99.7%, respectively. No grade 3 or 4 adverse reactions were observed in patients. Conclusions The scheme of target volume delineation and dose configuration in our study not only achieves excellent target volume coverage, but also reduces adverse reactions in patients, which achieves a 2-year LRC ideal for patients with early-stage NC-NKTL.
Niu Shaoqing*,Zhang Yujing,Wen Ge et al. Preliminary results of a phase Ⅱ prospective clinical study of early-stage nasal NK/T-cell lymphoma with extended involved-field intensity-modulated radiotherapy[J]. Chinese Journal of Radiation Oncology, 2015, 24(4): 377-381.
[1] 杨勇,张玉晶,林旭滨,等.放射治疗在早期结外鼻型NK/T细胞淋巴瘤综合治疗中的作用及预后分析[J].中华放射肿瘤学杂志, 2009,18(4):285-289.DOI:10.3760/cma.j.issn.1004-4221.2009.04.285. [2] Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage ⅠE and ⅡE nasal natural killer/T-cell lymphoma[J]. J Clin Oncol, 2006,24(1):181-189.DOI:10.1200/JCO.2005.03.2573. [3] Huang MJ, Jiang Y, Liu WP, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract[J]. Int J Radiat Oncol Biol Phys,2008,70(1):166-174.DOI:10.1016/j.ijrobp.2007.05.073. [4] 金晶,李晔雄,姚波,等.ⅠE~ⅡE期鼻腔NK/T细胞淋巴瘤的放疗效果分析[J].中华放射肿瘤学杂志,2006,15(2):108-113. [5] Koom WS, Chung EJ, Yang WI, et al. Angiocentric T-cell and NK/T-cell lymphomas:radiotherapeutic viewpoints[J]. Int J Radiat Oncol Biol Phys,2004,59(4):1127-1137.DOI:10.1016/j.ijrobp.2003.12.006. [6] Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma[J]. Cancer,2004,100(2):366-375.DOI:10.1002/cncr.11908. [7] Li YX, Liu QF, Wang WH, et al. Failure patterns and clinical implications in early stage nasal natural killer/T-cell lymphoma treated with primary radiotherapy[J]. Cancer,2011,117(22):5203-5211.DOI:10.1002/cncr.26167. [8] Shen Q, Ma X, Hu W, et al. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage Ⅰ-Ⅱ natural killer/T-cell lymphoma nasal type:dosimetric and clinical results[J]. Radiat Oncol,2013,8(1):152-159.DOI:10.1186/1748-717X-8-152. [9] Tomita N, KodairaT, Tachibana H, et al. A comparison of radiation treatment plans using IMRT with helical tomotherapy and 3D conformal radiotherapy for nasal natural liller/T-cell lymphoma[J]. Br J Radiol,2009,82(981):756-763. DOI:10.1259/bjr/83758373. [10] Wang H, Li YX, Wang WH, et al. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma[J]. Int J Radiat Oncol BiolPhys,2012,82(3):1115-1121.DOI:10.1016/j.ijrobp.2011.02.039. [11] Bi XW, Li YX, Fang H, et al. High-dose and extended-field intensity modulated radiation therapy for early-stage NK/T-cell lymphoma of Waldeyer′s ring:dosimetric analysis and clinical outcome[J]. Int J Radiat Oncol Biol Phys,2013,87(5):1086-1093.DOI:10.1016/j.ijrobp.2013.08.040. [12] Kim SJ, Kim BS, Choi CW, et al. Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract[J]. Leuk Lymphoma,2006,47(7):1265-1273.DOI:10.1080/10428190600565651. [13] International T-Cell lymphoma project. International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes[J]. J Clin Oncol,2008,26(25):4124-4130.DOI:10.1200/JCO.2008.16.4558. [14] Lee J, Suh C, ParkYH, et al. Extranodal natural killer T-cell lymphoma, nasal-type:a prognostic model from a retrospective multicenter study[J]. J Clin Oncol,2006,24(4):612-618.DOI:10.1200/JCO.2005.04.1384. [15] 牛绍清,张玉晶,杨勇,等.早期原发鼻腔与韦氏环NK/T细胞淋巴瘤临床特征和预后比较[J]. 中华放射肿瘤学杂志, 2013,22(5):352-356.DOI:10.3760/cma.j.issn.1004-4221.2013.05.004. [16] Grégoire V, Ang K, Budach W, et al. Delineation of the neck node levels for head and neck tumors:a 2013 update. DAHANCA, EORTC, HKNPCSG,NCIC CTG, NCRI, RTOG,TROG consensus guidelines[J]. Radiother Oncol,2014,110(1):172-181.DOI:10.1016/j.radonc.2013.10.010.
2015, Vol. 24 
